Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest ALS Stories

2013-10-17 16:25:07

Announcement follows Congressman Fattah's meeting with NeuroVigil CEO, Dr. Philip Low WASHINGTON, Oct. 17, 2013 /PRNewswire-USNewswire/ -- A new technology that will enable patients suffering from ALS --commonly known as Lou Gehrig's Disease--to communicate via brain monitor, will hold its first clinical trials in Philadelphia. Congressman Chaka Fattah (PA-02) was on hand for the announcement, made Tuesday at the BrainTech Israel conference in Tel Aviv. The announcement came...

Researchers Discover And Treat Toxic Effects Of ALS Mutation Using Neurons Made From Patients' Skin Cells
2013-10-16 16:30:46

Cell Press Researchers have discovered how the most common genetic abnormality in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) kills neurons and have successfully developed a therapeutic strategy to block this neurodegeneration in neurons made from the skin cells of ALS patients. The findings, which are published online in the October 16th issue of the Cell Press journal Neuron, have important implications for treating patients with these debilitating, currently...

2013-10-15 08:33:25

WASHINGTON, Oct. 15, 2013 /PRNewswire-USNewswire/ -- If he were here today, baseball's Lou Gehrig would be proud of his brothers from the Phi Delta Theta Fraternity. The Fraternity, of which Gehrig was a member during his days at Columbia University in the early 1920s, will be working with The ALS Association for a Service Learning Trip in May 2014. For this trip, Phi Delta Theta members will interact with people living with amyotrophic lateral sclerosis (ALS) and others from the ALS...

2013-10-10 08:30:24

ROCKVILLE, Md., Oct. 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase II trial testing Neuralstem's spinal cord stem cells, NSI-566, in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will speak at the American Neurological Association's (ANA) Annual Meeting in New Orleans, LA, on October 15(th) at 1:35 (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3752). Dr. Feldman,...

2013-10-09 08:29:05

First of Five Cohorts Completed in Dose Escalation Trial ROCKVILLE, Md., Oct. 9, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the University of Michigan Health System, in Ann Arbor, Michigan, treated its first two patients in the Phase II trial testing NSI-566 neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This completes the first cohort in Phase II, which is also being conducted at Emory University Hospital, in Atlanta,...

2013-09-26 08:28:39

Ted Harada, ALS Stem Cell Trial Patient, To Talk ROCKVILLE, Md., Sept. 26, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO, Richard Garr, will present at the Stem Cells & Regenerative Medicine Congress, on Monday, September 30 at 12:00 PM at the Hyatt Regency in Cambridge, MA (http://www.terrapinn.com/2013/stem-cells-usa-regenerative-medicine/index.stm). Mr. Garr will give an overview of Neuralstem's ongoing trial testing NSI-566 stem cells...

2013-09-10 08:32:10

ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University Hospital in Atlanta, Georgia. The Phase II dose escalation and safety trial, taking place at Emory and at the University of Michigan Health System, is designed to treat up to 15 patients in...

2013-09-10 08:31:29

Collaboration to Explore Compound that Regulates Neuroinflammation and Apoptosis CAMBRIDGE, Mass., Sept. 10, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into a research partnership with Anida Pharma, Inc., to investigate a potential treatment for ALS, also known as Lou Gehrig's disease. (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) Under the terms of the agreement with Anida, ALS TDI will...

2013-09-03 08:29:37

Live Webcast on Tuesday, September 10, at 11:40 a.m. EST ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 15(th) annual Rodman & Renshaw Healthcare Conference on Tuesday, September 10, at 11:40 a.m. EST, in Room 7.03, 7(th) Floor, of the Millennium Broadway Hotel in New York City. Garr will provide an overview of the company's upcoming NSI-566 cell therapy clinical trials, including...

2013-08-29 08:25:05

BOGOTA, Colombia, Aug. 29, 2013 /PRNewswire/ -- Precision StemCell (www.precisionstemcell.com), an outpatient treatment facility in Colombia, has successfully performed a breakthrough stem cell procedure that may soon improve the lives of everyone with ALS, or Lou Gehrig's disease. The new procedure consists of an advanced, image-guided injection of umbilical cord matrix stem cells into the patient's nerve roots at the point where they exit the spinal cord. "At our center in...